A5011874638- Liver Disease Diagnosis and Treatment
- Liver Disease and Transplantation
- Hepatitis C virus research
- Hepatitis B Virus Studies
- COVID-19 Clinical Research Studies
- Drug-Induced Hepatotoxicity and Protection
- Hepatocellular Carcinoma Treatment and Prognosis
- Alcohol Consumption and Health Effects
- Helicobacter pylori-related gastroenterology studies
- Hepatitis Viruses Studies and Epidemiology
- COVID-19 and healthcare impacts
- Esophageal and GI Pathology
- Pancreatic and Hepatic Oncology Research
- Organ Transplantation Techniques and Outcomes
- Gastroesophageal reflux and treatments
- Immunodeficiency and Autoimmune Disorders
- Chronic Lymphocytic Leukemia Research
- Gallbladder and Bile Duct Disorders
- HIV/AIDS drug development and treatment
- Adrenal and Paraganglionic Tumors
- Liver Diseases and Immunity
- Diagnosis and treatment of tuberculosis
- Cancer, Lipids, and Metabolism
- Folate and B Vitamins Research
- Complementary and Alternative Medicine Studies
University of California, San Francisco
2018-2024
California State University, Fresno
2018-2024
Community Regional Medical Center
2024
VA Central California Health Care System
2018-2019
University of Kansas Medical Center
2018-2019
University Medical Center
2018-2019
Creative Research Enterprises (United States)
2018
Queen's Medical Center
2008-2017
University of Hawaiʻi at Mānoa
2008-2016
University of Hawaii System
2013-2015
The third leading preventable cause of death in the United States is excessive alcohol consumption. Our study sought to assess impact coronavirus disease 2019 (COVID-19) on hospitalizations for alcohol-related hepatitis at a community hospital system. We hypothesized an increase cases requiring inpatient management, mirroring strain economic and societal norms imposed by COVID-19 pandemic.We performed retrospective chart review incidence patients presenting 3 hospitals Fresno, California,...
Objectives The study aimed to compare the risk of gastrointestinal infections among patients with and without metabolic dysfunction-associated fatty liver disease (MAFLD). Methods This was a population-based, retrospective, observational using data from National Inpatient Sample (NIS), largest all-payer US inpatient care database. Setting Hospitalisation adults aged ≥18 years old admitted in 2020 identified NIS. Patients were stratified by presence absence MAFLD. Participants 26.4 million...
The concept of frailty has gained importance, especially in patients with liver disease. Our study systematically investigated the effect on post-procedural outcomes undergoing transjugular intrahepatic portosystemic shunt (TIPS).We used National Inpatient Sample(NIS) 2016-2019 data to identify who underwent TIPS. Hospital risk score (HFRS) was classify as frail (HFRS>=5) and non-frail (HFRS<5). relationship between such death, shock, non-home discharge, length stay (LOS), LOS, total...
Patients with end-stage liver disease (ESLD) have a poor quality of life, which often worsens as severity increases. Palliative care (PC) has emerged management option in ESLD patients, especially for those who are not candidates transplant.
Abstract OBJECTIVE The objective of the present study was to compare practice patterns hospitalists and community physicians in care patients with congestive heart failure. DESIGN/PARTICIPANTS/SETTING a retrospective chart review 342 treated for failure at community‐based teaching hospital. MEASUREMENTS Use established therapeutic modalities utilization resources by nonhospitalists were compared. Outcome measures adjusted length stay (LOS), costs per case, in‐hospital mortality, acute renal...
Background: COVID-19 is associated with higher morbidity and mortality in patients chronic liver diseases (CLDs). However, our understanding of the long-term outcomes CLD limited. Methods: We conducted a multicenter, observational cohort study adult who were diagnosed before May 30, 2020, to determine clinical outcomes. used control group confirmed negative for COVID-19. Results: followed 666 (median age 58 years, 52.8% male) median 384 (interquartile range: 31–462) days. The was 8.1%; 3.6%...
Although 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors are well tolerated, a small subset of patients may develop autoimmune myopathy, classified as immune-mediated necrotizing myopathy. Statin-induced myopathy can present proximal muscle weakness and in some cases dysphagia respiratory distress. We two taking statins who developed found to have statin-induced Both were treated with immunosuppressive therapy: one did clinically, while the other had an aggressive form...
Studies have reported that the COVID-19 pandemic has led to an increase in alcohol consumption and alcohol-associated health problems general population. Our previous study documented a rise severe alcohol-related hepatitis cases requiring inpatient admission our hospital system early (2019 vs. 2020). This assesses rates of latter part (2021).